Tag: 上海夜网L

  • Five goalkeepers shortlisted for FIFA FIFPro World XI 2014

    first_imgFIFPro, the World Players’ Union, and FIFA today announced the five goalkeepers shortlisted for the FIFA FIFPro World XI 2014 as part of the final 55-man shortlist to be revealed on 1 December 2014.The FIFA FIFPro World XI is decided by the players, for the players. It involves votes from tens of thousands professional footballers worldwide. They select one goalkeeper, four defenders, three midfielders and three forwards.The shortlists for defenders, midfielders and forwards will be announced and published on FIFA.com on 26 November, 28 November and 1 December respectively.FIFPro and its national affiliates are responsible for gathering votes from professional footballers worldwide. It is the only global award that truly represents the views of those who play the beautiful game.The goalkeeper shortlist is:Manuel Neuer – was last year’s FIFA FIFPro World XI goalkeeper. Claudio Bravo – First nomination on the 55-man shortlist.Thibaut Courtois – he is making his debut on the 55-man shortlist.Iker Casillas – was the World XI goalkeeper for five straight years (2008-2012).Gianluigi Buffon – was the World XI goalkeeper in 2006 and 2007. He is the only goalkeeper to appear on all ten World XI shortlists since the introduction of the award in 2005last_img read more

  • No Plan B for LaLiga game in Miami after Barcelona withdraws

    first_imgBarça were and still are willing to play in Miami, but consider that the project will not prosper until there is an agreement between all parties involvedhttps://t.co/PWVMEPU9zz— FC Barcelona (@FCBarcelona) December 10, 2018Tebas explained he was yet to discuss the matter with Barcelona president Josep Maria Bartomeu and thanked Barcelona for allowing the process to get so far down the line.”I do not consider it a betrayal,” he added. “This was voluntary and until the last moment I could make a decision like that.”Barca wants unanimity and that will be very complicated. I can only thank them for helping us.” In October, FIFA president Gianni Infantino said soccer’s world governing body would not sanction the game, which was proposed as part of a 15-year agreement between Spain’s top flight and marketing partner Relevent Sports.On Monday, Barca withdrew from the planned match at the Dolphins’ Hard Rock Stadium, “after noting a lack of consensus over this proposal”. Related News LaLiga president Javier Tebas insists he has no plans to propose an alternative regular-season match in Miami next month after Barcelona pulled out of its proposed game against Girona.The prospect of playing a LaLiga game in the United States had been roundly criticized, with the Royal Spanish Football Federation and prominent players such as Barcelona defender Gerard Pique voicing their concerns. “The calendar was already established for a long time. There is no plan B,” Tebas told AS.”Taking the game to the U.S. is a very complicated issue. It is not easy and, if Barca has decided not to go …”We already said that it was a voluntary issue. We are going to try and change the opinion of Barcelona.”It is a very thoughtful decision of [Barca’s] board of directors.” Barcelona pulls out of plan to play LaLiga game in Miamilast_img read more

  • Some tumors use two levels of protection against immune system shows study

    first_imgIn research published today, Babraham Institute researchers have shown that some tumors use not one but two levels of protection against the immune system. Knocking out one level boosted the protective effects of the second and vice versa. The research demonstrates that a two-pronged approach targeting both cell types simultaneously may offer a promising route for the development of new cancer immunotherapies.The development and growth of a cancerous tumor often occurs despite a fully functioning immune system, capable of recognizing and killing cancer cells. Tumors hijack certain cells in our immune system to create a growth-permissive environment and give protection from the anti-tumor elements. In particular, tumors recruit immune cell allies, cells called tumor-associated macrophages (TAMs) and regulatory T cells (Treg), to evade immune attack.Specifically inhibiting the recruitment of TAMs by blocking the actions of a protein called colony-stimulating factor 1 (CSF1) reduces tumor growth in mouse models. Although clinical trials of inhibitors targeting TAMs are underway, results in patients haven’t been as effective as hoped. A lack of understanding of how TAMs promote tumor progression potentially limits the therapeutic value of these inhibitors.Likewise, inhibiting the action of Treg cells in mice by inactivating a key enzyme called PI3K delta gives protection against a range of tumors. A PI3K delta inhibitor is approved for treatment of chronic lymphocytic leukaemia (CLL) and follicular non-Hodgkin lymphoma (NHL), but the potential for PI3K delta inhibitors for the treatment of solid cancers in humans is yet to be demonstrated.Related StoriesStudy: Nearly a quarter of low-risk thyroid cancer patients receive more treatment than necessaryNew protein target for deadly ovarian cancerStudy reveals link between inflammatory diet and colorectal cancer riskThe research published today used a mouse model of colorectal cancer to explore the synergy between TAMs and Treg cells, showing that each cell type was able to compensate for the effects of the loss of the other to maintain the tumor’s protection from the immune system. However, jointly inhibiting TAMs and Treg cells substantially inhibited tumor growth.Dr David Gyori, first author on the paper, said: “Strikingly, preventing tumor immunosuppression by both TAMs and Treg cells caused almost complete tumor rejection by the immune system and half of the mice became completely tumor-free. Taken together, our findings provide a convincing rationale for assessing the clinical value of combinatorial therapies targeting the CSF1 receptor and PI3K delta.”Professor Klaus Okkenhaug, one of the authors on the study by Gyori et al. and a parallel study by Lim et al. said: “Harnessing the power of the immune system to kill cancer cells is becoming a successful therapeutic strategy. These studies demonstrate the importance of fully understanding the interplay between the many elements of the immune system to ensure that combinatorial therapies are both synergistic and effective.” Source:https://www.babraham.ac.uk/news/2018/06/breaking-through-a-tumours-defences Jun 8 2018 Researchers identify the dominant immune cells contributing to tumor tolerance by the immune system Silencing the tumor-shielding cells of the immune system allows T cell attack on tumors and restricts tumor growth Research findings suggest new targets for cancer immunotherapieslast_img read more